Alpha 2.0
Login Register
» Authors » M Andreeff

M Andreeff

Explore the profile of M Andreeff including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 313
Citations 5799
Followers 0
Related Specialties
Oncology
Hematology
General Medicine
Top 10 Co-Authors
M Konopleva
S Zhao
H Kantarjian
S OBrien
S M Kornblau
U Consoli
Z Estrov
E Estey
A Younes
B D Clarkson
Published In
Leukemia
Blood
Br J Haematol
Leuk Lymphoma
Clin Cancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Retraction Note: MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex
Konopleva M, Milella M, Ruvolo P, Watts J, Ricciardi M, Korchin B, et al.
Leukemia . 2024 Jul; 38(9):2072. PMID: 39025987
No abstract available.
2.
Correction to: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia
Garzon R, Pichiorri F, Palumbo T, Visentini M, Aqeilan R, Cimmino A, et al.
Oncogene . 2022 May; 41(25):3452-3453. PMID: 35546352
No abstract available.
3.
Measurement of relative lung perfusion with electrical impedance and positron emission tomography: an experimental comparative study in pigs
Bluth T, Kiss T, Kircher M, Braune A, Bozsak C, Huhle R, et al.
Br J Anaesth . 2019 Jun; 123(2):246-254. PMID: 31160064
Background: Electrical impedance tomography (EIT) with indicator dilution may be clinically useful to measure relative lung perfusion, but there is limited information on the performance of this technique. Methods: Thirteen...
4.
Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo
Zhou H, Mak P, Mu H, Mak D, Zeng Z, Cortes J, et al.
Leukemia . 2017 Mar; 31(10):2065-2074. PMID: 28321124
Tyrosine kinase inhibitor (TKI) resistance and progression to blast crisis (BC), both related to persistent β-catenin activation, remain formidable challenges for chronic myeloid leukemia (CML). We observed overexpression of β-catenin...
5.
A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia
Uy G, Rettig M, Stone R, Konopleva M, Andreeff M, McFarland K, et al.
Blood Cancer J . 2017 Mar; 7(3):e542. PMID: 28282031
No abstract available.
6.
The novel BMI-1 inhibitor PTC596 downregulates MCL-1 and induces p53-independent mitochondrial apoptosis in acute myeloid leukemia progenitor cells
Nishida Y, Maeda A, Kim M, Cao L, Kubota Y, Ishizawa J, et al.
Blood Cancer J . 2017 Feb; 7(2):e527. PMID: 28211885
Disease recurrence is the major problem in the treatment of acute myeloid leukemia (AML). Relapse is driven by leukemia stem cells, a chemoresistant subpopulation capable of re-establishing disease. Patients with...
7.
Treatment of Philadelphia Chromosome Positive (Ph +) Chronic Myelogenous Leukemia in Blast Crisis and Ph + Acute Leukemia with High Dose Cytosine Arabinoside (HDARAC)
Kempin S, Arlin Z, Berman E, Gee T, Mertelsmann R, Andreeff M, et al.
Leuk Lymphoma . 2016 Jul; 4(2):111-6. PMID: 27462940
High dose cytosine arabinoside (HDARAC) was administered to eleven patients in the blastic phase of Philadelphia (Ph) chromosome positive chronic myelogenous leukemia (CML). Four patients presented in blastic phase and...
8.
GD3 synthase regulates epithelial-mesenchymal transition and metastasis in breast cancer
Sarkar T, Battula V, Werden S, Vijay G, Ramirez-Pena E, Taube J, et al.
Oncogene . 2014 Aug; 34(23):2958-67. PMID: 25109336
The epithelial-mesenchymal transition (EMT) bestows cancer cells with increased stem cell properties and metastatic potential. To date, multiple extracellular stimuli and transcription factors have been shown to regulate EMT. Many...
9.
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia
Ravandi F, Arana Yi C, Cortes J, Levis M, Faderl S, Garcia-Manero G, et al.
Leukemia . 2014 Feb; 28(7):1543-5. PMID: 24487412
No abstract available.
10.
Apoptosis repressor with caspase recruitment domain is regulated by MAPK/PI3K and confers drug resistance and survival advantage to AML
Mak P, Mak D, Mu H, Shi Y, Ruvolo P, Ruvolo V, et al.
Apoptosis . 2013 Dec; 19(4):698-707. PMID: 24337870
The apoptosis repressor with caspase recruitment domain (ARC) protein is known to suppress both intrinsic and extrinsic apoptosis. We previously reported that ARC expression is a strong, independent adverse prognostic...